Drought Ending? Shanghai’s STAR Market Considers Two IPO Applicants

 
• By Dexter Jie Yan

With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.

China biotech IPO
Two Chinese biotechs will need to convince STAR for successful IPO applications • Source: Shutterstock

More from China

More from Focus On Asia